Neurocrine Biosciences, Inc. (NBIX) Income Statement Analysis

See more : Magnum Ventures Limited (MAGNUM.BO) Income Statement Analysis – Financial Results

Complete financial analysis of Neurocrine Biosciences, Inc. (NBIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neurocrine Biosciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

Viskase Companies, Inc. (VKSC) Income Statement Analysis – Financial Results
Ebiquity plc (EBQ.L) Income Statement Analysis – Financial Results
Texmo Pipes and Products Limited (TEXMOPIPES.NS) Income Statement Analysis – Financial Results
Urbana Corporation (URB-A.TO) Income Statement Analysis – Financial Results
Ananda Development Public Company Limited (ANAN.BK) Income Statement Analysis – Financial Results

Neurocrine Biosciences, Inc. (NBIX)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.neurocrine.com

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996
Revenue	1.89B	1.49B	1.13B	1.05B	788.10M	451.24M	161.63M	15.00M	19.77M	0.00	2.92M	53.14M	77.41M	33.50M	2.95M	3.98M	1.22M	39.23M	123.89M	85.18M	139.08M	18.05M	41.24M	14.59M	16.80M	16.00M	26.10M	19.20M
Cost of Revenue	39.70M	23.20M	14.30M	10.10M	7.40M	4.89M	1.25M	35.90M	33.80M	14.40M	13.80M	11.60M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.20M	-2.10M	-1.70M	-1.30M	-1.00M
Gross Profit	1.85B	1.47B	1.12B	1.04B	780.70M	446.35M	160.37M	-20.90M	-14.03M	-14.40M	-10.88M	41.54M	77.41M	33.50M	2.95M	3.98M	1.22M	39.23M	123.89M	85.18M	139.08M	18.05M	41.24M	16.79M	18.90M	17.70M	27.40M	20.20M
Gross Profit Ratio	97.90%	98.44%	98.74%	99.03%	99.06%	98.92%	99.22%	-139.33%	-70.97%	0.00%	-372.76%	78.17%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	115.07%	112.50%	110.63%	104.98%	105.21%
Research & Development	565.00M	463.80M	328.10M	275.00M	200.00M	160.52M	121.83M	94.29M	81.49M	46.43M	39.25M	37.16M	30.95M	31.15M	35.81M	55.29M	81.99M	97.68M	106.63M	115.07M	177.27M	108.94M	74.27M	40.23M	29.20M	21.80M	19.90M	12.60M
General & Administrative	0.00	0.00	0.00	0.00	0.00	248.93M	169.91M	68.08M	32.48M	17.99M	13.35M	13.44M	12.54M	16.07M	14.83M	20.24M	37.48M	54.87M	42.33M	22.44M	20.59M	12.72M	10.86M	9.96M	7.50M	6.60M	5.70M	3.70M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-82.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	887.60M	752.70M	583.30M	433.30M	354.10M	248.93M	169.91M	68.08M	32.48M	17.99M	13.35M	13.44M	12.46M	16.07M	14.83M	20.24M	37.48M	54.87M	42.33M	22.44M	20.59M	12.72M	10.86M	9.96M	7.50M	6.60M	5.70M	3.70M
Other Expenses	143.90M	0.00	105.30M	164.50M	154.27M	0.00	-20.00K	13.00K	11.00K	18.00K	16.00K	14.00K	42.23M	73.29M	70.99M	15.74M	94.00M	90.96M	97.44M	87.91M	80.57M	96.58M	0.00	2.20M	2.10M	1.70M	1.30M	1.00M
Operating Expenses	1.60B	1.22B	911.40M	708.30M	554.10M	409.46M	291.73M	162.37M	113.97M	64.41M	52.60M	51.69M	43.41M	47.22M	50.64M	91.27M	213.47M	152.55M	148.96M	137.51M	197.87M	121.66M	85.12M	52.39M	38.80M	30.10M	26.90M	17.30M
Cost & Expenses	1.64B	1.24B	925.70M	718.40M	561.50M	414.35M	292.99M	162.37M	113.97M	64.41M	52.60M	51.69M	43.41M	47.22M	50.64M	91.27M	213.47M	152.55M	148.96M	137.51M	197.87M	121.66M	85.12M	50.19M	36.70M	28.40M	25.60M	16.30M
Interest Income	0.00	11.20M	3.80M	12.60M	19.21M	0.00	0.00	2.84M	1.93M	629.00K	400.00K	489.00K	435.00K	397.00K	691.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	4.60M	7.10M	25.80M	32.80M	32.00M	30.53M	19.52M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.03M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	21.30M	15.60M	10.90M	8.60M	7.45M	4.02M	2.40M	1.50M	1.01M	827.00K	671.00K	657.00K	694.00K	1.44M	3.18M	7.61M	9.40M	10.57M	10.09M	7.08M	3.69M	3.10M	2.65M	2.20M	2.10M	1.70M	1.30M	1.00M
EBITDA	358.00M	264.60M	218.70M	336.10M	226.60M	56.40M	-120.62M	-139.59M	-87.92M	-63.58M	-49.01M	2.11M	34.62M	-13.72M	-47.86M	-73.98M	-193.97M	-102.75M	-14.98M	-45.25M	-55.10M	-100.52M	-41.23M	-33.40M	-17.80M	-10.70M	1.80M	3.90M
EBITDA Ratio	18.97%	16.73%	18.33%	31.31%	28.75%	8.18%	-81.29%	-1,024.27%	-503.13%	0.00%	-1,824.25%	-3.98%	39.32%	-36.67%	-1,501.32%	-1,650.74%	-8,891.99%	-261.89%	-12.09%	-52.97%	-52.62%	-558.23%	-101.02%	-236.15%	-107.14%	-20.63%	-11.88%	2.60%
Operating Income	250.90M	249.00M	196.90M	318.90M	219.15M	36.90M	-131.36M	-147.37M	-94.20M	-64.41M	-49.68M	1.45M	33.92M	-13.72M	-53.67M	-87.30M	-212.24M	-113.32M	-25.07M	-52.33M	-58.79M	-103.62M	-43.88M	-35.60M	-19.90M	-12.40M	500.00K	2.90M
Operating Income Ratio	13.30%	16.73%	17.37%	30.49%	27.81%	8.18%	-81.27%	-982.48%	-476.51%	0.00%	-1,701.88%	2.72%	43.82%	-40.96%	-1,817.47%	-2,196.18%	-17,340.03%	-288.82%	-20.24%	-61.44%	-42.27%	-574.20%	-106.40%	-244.04%	-118.45%	-77.50%	1.92%	15.10%
Total Other Income/Expenses	81.20M	-35.10M	-1.10M	-56.30M	-25.80M	-15.05M	-11.18M	6.28M	5.27M	3.87M	3.59M	3.58M	3.65M	5.75M	2.63M	-1.32M	4.94M	6.11M	2.88M	6.64M	28.69M	9.08M	7.09M	7.10M	200.00K	-7.40M	4.80M	3.20M
Income Before Tax	332.10M	213.90M	101.40M	106.70M	46.50M	21.84M	-142.54M	-141.09M	-88.93M	-60.54M	-46.09M	5.03M	37.57M	-7.97M	-88.61M	-88.61M	-207.30M	-107.21M	-22.19M	-45.69M	-30.10M	-94.54M	-36.79M	-28.51M	-19.70M	-19.80M	5.30M	6.10M
Income Before Tax Ratio	17.60%	14.37%	8.95%	10.20%	5.90%	4.84%	-88.19%	-940.60%	-449.84%	0.00%	-1,578.97%	9.46%	48.53%	-23.78%	-3,000.78%	-2,229.26%	-16,936.19%	-273.25%	-17.91%	-53.65%	-21.64%	-523.89%	-89.21%	-195.41%	-117.26%	-123.75%	20.31%	31.77%
Income Tax Expense	82.40M	59.40M	11.80M	-300.60M	9.50M	730.00K	17.10M	-7.72M	-6.27M	-4.68M	-4.24M	-4.22M	-4.26M	0.00	173.00K	1.32M	-4.94M	0.00	0.00	79.00K	158.00K	-9.08M	120.00K	302.00K	-3.10M	7.60M	200.00K	200.00K
Net Income	249.70M	154.50M	89.60M	407.30M	37.00M	21.11M	-142.54M	-141.09M	-88.93M	-60.54M	-46.09M	5.03M	37.57M	-7.97M	-51.04M	-88.61M	-207.30M	-107.21M	-22.19M	-45.77M	-30.26M	-94.54M	-36.91M	-28.81M	-16.80M	-20.00M	5.10M	5.90M
Net Income Ratio	13.23%	10.38%	7.90%	38.94%	4.69%	4.68%	-88.19%	-940.60%	-449.84%	0.00%	-1,578.97%	9.46%	48.53%	-23.78%	-1,728.34%	-2,229.26%	-16,936.19%	-273.25%	-17.91%	-53.74%	-21.75%	-523.89%	-89.50%	-197.48%	-100.00%	-125.00%	19.54%	30.73%
EPS	2.56	1.61	0.95	4.37	0.40	0.22	-1.62	-1.63	-1.05	-0.81	-0.69	0.08	0.68	-0.15	-1.30	-2.30	-5.45	-2.84	-0.60	-1.26	-0.93	-3.10	-1.42	-1.30	-0.88	-1.10	0.30	0.39
EPS Diluted	2.47	1.56	0.92	4.16	0.39	0.22	-1.62	-1.63	-1.05	-0.81	-0.69	0.08	0.67	-0.15	-1.30	-2.30	-5.45	-2.84	-0.58	-1.26	-0.93	-3.10	-1.42	-1.30	-0.88	-1.10	0.28	0.36
Weighted Avg Shares Out	97.70M	95.80M	94.60M	93.10M	91.63M	95.40M	87.99M	86.56M	84.50M	74.58M	66.80M	65.62M	55.18M	52.82M	39.14M	38.45M	38.01M	37.72M	36.76M	36.20M	32.37M	30.49M	26.03M	22.12M	19.07M	18.14M	17.00M	15.13M
Weighted Avg Shares Out (Dil)	101.00M	98.90M	97.90M	97.80M	95.73M	95.40M	88.09M	86.71M	84.50M	74.58M	66.99M	66.95M	56.35M	52.82M	39.14M	38.45M	38.01M	37.72M	37.99M	36.20M	32.37M	30.49M	26.03M	22.12M	19.07M	18.14M	18.21M	16.39M

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

October 23, 2024zacks.com

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

October 10, 2024seekingalpha.com

Neurocrine Biosciences' Ingrezza has grown into a multibillion-dollar drug, but the company's stock has underperformed the S&P 500 since 2019. Neurocrine's NBI-1117568 demonstrated encouraging Phase 2 schizophrenia data, though dose inconsistencies raised questions about efficacy. The stock's recent decline is...

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

October 9, 2024prnewswire.com

Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO , Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00...

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use

September 30, 2024prnewswire.com

KINECT®-HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for the Treatment of Huntington's Disease Chorea Findings Presented at the 2024 MDS International Congress of Parkinson's...

Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit

September 19, 2024prnewswire.com

SAN DIEGO , Sept. 19, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit at 11:00 a.m.

Neurocrine's experimental drug misses primary goal in schizophrenia trial

September 12, 2024reuters.com

Neurocrine Biosciences said its experimental drug did not achieve the primary goal in a mid-stage trial aimed at improving cognitive function in patients with schizophrenia.

Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

September 12, 2024prnewswire.com

Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with Schizophrenia Results Confounded by Variability in Cognition Measures Across Population Studied and Potential Imbalance in Baseline Characteristics of Enrolled Subjects Neurocrine...